1,4-dihydropyridine has been researched along with Parkinson Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Friis, S; Olsen, JH; Qian, L; Rhodes, SL; Ritz, B; Schernhammer, E | 1 |
Guzman, JN; Ilijic, E; Kondapalli, J; Sanchez-Padilla, J; Schumacker, PT; Surmeier, DJ; Wokosin, D | 1 |
2 other study(ies) available for 1,4-dihydropyridine and Parkinson Disease
Article | Year |
---|---|
L-type calcium channel blockers and Parkinson disease in Denmark.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Community Health Planning; Denmark; Dihydropyridines; Female; Humans; Logistic Models; Male; Middle Aged; Outpatients; Parkinson Disease; Prescription Drugs; Registries; Retrospective Studies | 2010 |
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.
Topics: Animals; Biological Clocks; Brain; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Cyclophilins; Dihydropyridines; Dopamine; Gene Deletion; Ion Channels; Iridoid Glycosides; Iridoids; Male; Mice; Mice, Transgenic; Mitochondria; Mitochondrial Proteins; Neurons; Oncogene Proteins; Oxidative Stress; Parkinson Disease; Peptidyl-Prolyl Isomerase F; Peroxiredoxins; Protein Deglycase DJ-1; Purines; Superoxides; Uncoupling Protein 1 | 2010 |